Few Highlights from the Earnings Release and Conference Call.
Just wanted to post a few highlights from the Earnings Release and the Conference Call. I'll be updating my ALXA Summary thread later with this and other information, but until then I just wanted to make a quick post about it.
- Alexza currently has enough money to fund their planned operations though the Second Quarter of 2011. - If milestones are met under the Biovail Corporation deal, they will have enough money to fund their operations into 2012.
- If approved in October of this year, AZ-004 is planned to launch in Q1 of 2010 in North America. - ALXA is looking to license and partner with other companies to market and commercialize AZ-004 outside of North America. - ALXA is expected to begin purchasing manufacturing and raw components for AZ-004 in a few months.
- ALXA is expecting to begin advancing at least one of their other product candidates within the second half of this year. - Which product candidate ALXA advances first will depend on whether they want to partner with another company for their next product or whether they want to proceed by themselves with their next product. - ALXA is looking to find partners for some of their other products in 2010. - In additional to ALXA's current 6 product candidates currently with INDs and clinical trials, there are 5 other compounds that haven't been publicly announced that are viable for use of the Staccato System, which they are currently eventuating (along with other compounds). - Any announcements involving these will likely be made outside of their quarterly reports.